Heart disease: 3 drugs report positive clinical trials
Top stories today:
- Heart disease: 3 drugs report positive clinical trials
- Humane Ai Pin out only in 2024, product still not fully built out
- OpenAI, Character AI in talks to raise money
- Israel continues to encircle hospitals used by Hamas, IDF says
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).
All times are ET.
1. Heart disease: 3 drugs report positive clinical trials
VERVE-101's single-shot gene therapy reduced LDL-C (“bad cholesterol”) by up to 55% in a Phase 1 clinical trial.
Lepodisiran, a once-a-year shot, reduced lipoprotein(a), or Lp(a), by up to 94%, also in a Phase 1.
Wegovy reduced cardiovascular-related death by 20% in a 17.6K patient study. Wegovy is the branded name of semaglutide, already approved for weight loss.
Among the most sought-after corporate benefits.
2. Humane Ai Pin out only in 2024, product still not fully built out
Screenless smartphone that leverages OpenAI’s APIs to answer questions, take pictures (video soon), text and call people, and “catch me up.”
Confirmed at $699 + $24/mo.
No App Store, but comes with Tidal for music, potential Slack, Microsoft, Google integration.
Our view: the future of computing is likely AR (more screens, not fewer ones) and Apple can copy voice computing features with Siri
Siri with Apple’s new LLM can quickly obsolete the Ai Pin. Why not use my existing AirPods and talk to Siri, rather than pay $699 + $24/mo for a new device?
Not even founding investor Sam Altman is bullish on Humane: “That will be up to customers to decide. Maybe it’s a bridge too far, or maybe people are like, ‘This is much better than my phone.’ Plenty of technology that looked like a sure bet ends up selling for 90 percent off at Best Buy.”
3. Americans urge for a SECOND PASSPORT as the one-year countdown for the 2024 presidential election begins*
In search of a hedge against civil instability, more and more Americans turn towards a Citizenship-by-Investment program.
Having a Second Passport in 2023 is no longer a luxury, but a reasonable and necessary investment into your family’s safety. See precise calculations here.
Watch this 5-minute webinar to learn everything you need to know about a Second Citizenship as an Insurance Policy and how you can obtain one.
4. OpenAI, Character AI in talks to raise money
5. Israel continues to encircle hospitals used by Hamas, IDF says
6. BayAreaTimesGPT: we create our own custom GPT
Update yourself on the latest business and tech news.
Ask questions on the latest apps and gadgets.
Do anything else that ChatGPT is capable of: producing images, text, searching the web, etc.
7. Interesting videos, posts, and memes
8. Other headlines
Spatial video arrives in iOS 17 beta: review.
Didi’s revenue +25% to $7.0B in Q3.
iOS 18: Apple continues to move slowly as it debugs iOS 17.
Google’s plan to kill cookies may be delayed until 2025.
Deel at $400M ARR, from $300M in Jan.
Meta Quest to be sold in China late 2024, 14 years after Meta left country.
Foxconn uses SpaceX to launch 2 inaugural low-earth orbit satellites.
Sidebar is a leadership program that accelerates your career.*
Sportradar: NBA player tracking measures usage like never before.*
Tech & law
Longevity Week 2023 kicks off today in UK.
Madrigal presents strong Phase 3 data for NASH.
FDA approves 1st OTC home antigen test for Covid-19, ~4 years late.
Rare blood clotting disorder: 1st treatment approved by FDA.
OrsoBio raises $60M for small molecules for obesity, NASH.
GLP-1 weight loss drugs must tackle muscle loss problem: AZ CEO.
Was this newsletter forwarded to you? Sign up here. Liked it? Forward it to friends and get rewards (see below).
What did you think of today's newsletter?
Disclaimer: The Bay Area Times is a news publisher. All statements and expressions herein are the sole opinions of the authors or paid advertisers. The information, tools, and material presented are provided for informational purposes only, are not financial advice, and are not to be used or considered as an offer to buy or sell securities; and the publisher does not guarantee their accuracy or reliability. You should do your own research and consult an independent financial adviser before making any investments. Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein. Assets mentioned may be owned by members of the Bay Area Times team.